A U.S. supply guide · Read on 27 October 2026
The sources behind the shortage story
FDA decisions, supply records and explanations of the rules, with a note on what each one tells you.
A date is part of a source
These are the sources behind the guide. For a past turning point, the FDA decision explains what changed. For today’s national supply question, the shortage database is the place to return.
The two orders below cover semaglutide and tirzepatide injections. Later updates explain how the compounding rules changed afterward. A notice about one medicine or form doesn’t settle the status of another.
The notes say what each source helps explain. They don’t decide what treatment fits you; that needs a personal care conversation.
A delivery reaches one receiving door. FDA’s national supply finding answers a wider question, and keeps the date on which it was made.
The public readings
FDA’s shortage and compounding timeline
Semaglutide and tirzepatide shortage decisions, the 2025 wind-down dates and the 1 April 2026 policy update.
U.S. Food and Drug Administration · Accessed 27 October 2026
Declaratory Order: Resolution of Shortages of Semaglutide Injection Products
The 21 February 2025 semaglutide decision, including the separate 2022 Wegovy and Ozempic listings.
U.S. Food and Drug Administration · Accessed 27 October 2026
Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products
The 19 December 2024 tirzepatide decision, replacing the October decision after another review.
U.S. Food and Drug Administration · Accessed 27 October 2026
Frequently Asked Questions about Drug Shortages
How a national shortage differs from trouble finding a medicine locally.
U.S. Food and Drug Administration · Accessed 27 October 2026
Compounding and the FDA: Questions and Answers
What compounding means, how oversight works and why compounded drugs are not approved generics.
U.S. Food and Drug Administration · Accessed 27 October 2026
Understanding the Risks of Compounded Drugs
How contamination or an incorrect amount of active ingredient can cause serious harm.
U.S. Food and Drug Administration · Accessed 27 October 2026
Information for Outsourcing Facilities
The manufacturing, inspection and reporting duties of registered outsourcing facilities.
U.S. Food and Drug Administration · Accessed 27 October 2026
FDA alert about dosing errors with compounded injectable semaglutide
The July 2024 alert about reported dosing errors with compounded injectable semaglutide, some involving hospital care.
U.S. Food and Drug Administration · Accessed 27 October 2026
Compounding when Drugs are on FDA’s Drug Shortages List
Which copy restrictions change during shortages, and which other conditions remain.
U.S. Food and Drug Administration · Accessed 27 October 2026
Prescription Requirement Under Section 503A — guidance overview
The introduction to FDA’s guidance on prescriptions for identified individual patients.
U.S. Food and Drug Administration · Accessed 27 October 2026
Prescription Requirement Under Section 503A — full guidance
The full guidance on individual prescriptions and limited preparation ahead of them.
U.S. Food and Drug Administration · Accessed 27 October 2026
Drug Shortage Staff
How manufacturer reports help FDA keep shortage information up to date.
U.S. Food and Drug Administration · Accessed 27 October 2026
NLM Web Policies — medical information
The difference between general medical information and advice about your own care.
U.S. National Library of Medicine · Accessed 27 October 2026
Drug Shortages — search and reporting routes
How to search for a medicine and report a possible shortage.
U.S. Food and Drug Administration · Accessed 27 October 2026
FDA Drug Shortages database
The national database: current shortages, resolved shortages and product discontinuations.
U.S. Food and Drug Administration · Accessed 27 October 2026
Questions and Answers: Outsourcing Facility Registration
Why registering a facility does not prove compliance or approve its medicines.
U.S. Food and Drug Administration · Accessed 27 October 2026